HOUSTON, Aug. 27, 2020 /PRNewswire/ -- Moleculin Biotech,
Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical
stage pharmaceutical company with a broad portfolio of drug
candidates targeting highly resistant tumors, today announced that
Walter Klemp, Chairman and Chief
Executive Officer, will present at the LD Micro 500 Virtual
Investor Conference being held virtually on Tuesday, September 1st, at
4:40pm ET.
Details of the presentation are below:
Event:
|
LD Micro 500 Virtual
Investor Conference
|
Date:
|
September
1st, 2020
|
Time:
|
4:40pm ET
|
Link:
|
https://www.webcaster4.com/Webcast/Page/2019/36737
|
Additionally, the Company will hold 1-on-1 virtual investor
meetings at the conference. Investors attending the conference
virtually who are interested in meeting with Company management
should contact their LD Micro representatives.
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a clinical stage pharmaceutical
company focused on the development of a broad portfolio of oncology
drug candidates for the treatment of highly resistant tumors and
viruses. The Company's clinical stage drugs are: Annamycin, a Next
Generation Anthracycline, designed to avoid multidrug resistance
mechanisms with little to no cardiotoxicity being studied for the
treatment of relapsed or refractory acute myeloid leukemia, more
commonly referred to as AML, WP1066, an Immune/Transcription
Modulator capable of inhibiting p-STAT3 and other oncogenic
transcription factors while also stimulating a natural immune
response, targeting brain tumors, pancreatic cancer and hematologic
malignancies, and WP1220, an analog to WP1066, for the topical
treatment of cutaneous T-cell lymphoma. Moleculin is also engaged
in preclinical development of additional drug candidates, including
other Immune/Transcription Modulators, as well as WP1122 and
related compounds capable of Metabolism/Glycosylation
Inhibition.
For more information about the Company, please visit
http://www.moleculin.com.
Contacts
James Salierno
/ Carol Ruth
The Ruth Group
973-255-8361 / 917-859-0214
jsalierno@theruthgroup.com
cruth@theruthgroup.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/moleculin-to-present-at-ld-micro-500-virtual-investor-conference-301119466.html
SOURCE Moleculin Biotech, Inc.